Skip to main content
. Author manuscript; available in PMC: 2011 Jul 9.
Published in final edited form as: Cell. 2010 Jul 9;142(1):39–51. doi: 10.1016/j.cell.2010.06.018

Figure 1. In vivo screen for pro-neurogenic molecules. (See also Figure S1 and Table S1.).

Figure 1

(A) The total number of BrdU+ cells in the SGZ doubled following seven day infusion with FGF-2 relative to vehicle. Each pool of ten compounds was tested for pro-neurogenic efficacy in two mice, and 10 pools displayed efficacy comparable to FGF-2 infusion. The majority of pools displayed no effect. (B) In vivo evaluation in 4 mice each of the ten individual compounds in pool #7 revealed exclusive activity for compound #3. Immunohistochemically-visualized BrdU incorporation in the SGZ is notably greater in animals infused with either pool #7 or compound #3 from pool #7 relative to vehicle-infused animals. All micrographs were taken at the same magnification. (scale bar = 200 μm). (C) P7C3 concentration in mouse brain tissue correlated with oral dosing. Pro-neurogenic efficacy of P7C3 was roughly double that of vehicle at doses ranging from 5 to 40 mg/kg. At decreasing dosage of P7C3 the amount of neurogenesis decreased accordingly, until reaching levels no greater than vehicle at compound doses below 1.0 mg/kg. In all graphs data are expressed as mean +/- SEM.